Key result
Monthly alirocumab dosing yields similar major cardiovascular events rates to biweekly dosing with better persistence.
Why the study?
Real-world data comparing different alirocumab dosing intervals with respect to lipid outcomes, medication adherence, and cardiovascular events in high-risk patients were limited.
Does a monthly alirocumab dosing regimen improve 12-month major adverse cardiovascular events, medication adherence, and LDL-C goal attainment compared to a biweekly regimen in adults prescribed alirocumab in Hong Kong?
Cohort (n=2,012)
Yes
Does a monthly alirocumab dosing regimen improve 12-month major adverse cardiovascular events, medication adherence, and LDL-C goal attainment compared to a biweekly regimen in adults prescribed alirocumab in Hong Kong?
In a real-world Hong Kong cohort, monthly alirocumab dosing was associated with better treatment persistence and higher LDL-C target attainment than biweekly dosing, with similar 12-month MACE rates.
Answers are grounded in this paper and cite their sources.
No MACE difference between alirocumab regimens; leaves open optimal dosing and requires randomized confirmation.
Background Alirocumab, a PCSK9 inhibitor, is widely used in Hong Kong for managing dyslipidaemia in high-risk patients. However, real-world data comparing different dosing intervals are limited. Understanding whether dosing frequency influences lipid outcomes, medication adherence, and cardiovascular events may inform clinical practice and healthcare planning. Purpose This study aimed to evaluate the clinical and lipid outcomes of patients prescribed biweekly versus monthly alirocumab across Hong Kong, with a subgroup analysis focusing on patients with acute coronary syndrome (ACS). Methods A retrospective territory-wide cohort study was conducted, including all adults prescribed alirocumab between June 1, 2020, and December 31, 2025. Patients were categorized according to dosing frequency (biweekly or monthly). The primary outcome was 12-month major adverse cardiovascular events (MACE), comprising myocardial infarction, stroke, coronary revascularization (PCI/CABG), or cardiovascular death. Secondary outcomes included compliance (defined as discontinuation of therapy) and achievement of LDL-cholesterol (LDL-C) goals: <1.4 mmol/L, <1.8 mmol/L, and >50% reduction from baseline. Subgroup analyses were performed for patients with ACS. Statistical comparisons were conducted using appropriate inferential tests. Results A total of 2012 patients were included, with 72.0% receiving biweekly and 28.0% monthly dosing. At 12 months, there was no statistically significant difference in the incidence of MACE between groups (8.6% vs. 8.9%; p=0.829). Monthly dosing was associated with superior treatment persistence (83.7% vs. 77.2%; p=0.001) and higher proportions achieving LDL-C targets at all thresholds: <1.4 mmol/L (64.8% vs. 54.0%; p=<0.001), <1.8 mmol/L (75.5% vs. 66.2%; p=0.002), and >50% LDL reduction (56.6% vs. 48.0%; p=0.007). In the ACS subgroup (n=404), both regimens demonstrated comparable rates of MACE and lipid control (all p>0.05). Conclusions In this real-world Hong Kong cohort, monthly alirocumab dosing led to better adherence and LDL target attainment but similar cardiovascular outcomes compared with biweekly dosing. Among ACS patients, efficacy was comparable. Monthly dosing appears to be a convenient and effective option for maintaining lipid control without compromising safety.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) conducted a cohort in Dyslipidaemia (with acute coronary syndrome subgroup) (n=2,012). Monthly alirocumab dosing vs. Biweekly alirocumab dosing was evaluated on 12-month major adverse cardiovascular events (MACE), comprising myocardial infarction, stroke, coronary revascularization (PCI/CABG), or cardiovascular death (p=0.829). Monthly alirocumab dosing resulted in similar 12-month major cardiovascular events rates compared with biweekly dosing, with superior persistence and LDL-C goal attainment.
Synapse has enriched 10 related papers. Consider them for comparative context: